💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Upadacitinib

CHEMBL3622821 Phase 4 Đã phê duyệt Small molecule
Half-Life
9-14 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
380.4 g/mol
LogP
2.7
Phase
4

This oral JAK1-selective inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease in adults who have not responded adequately to other treatments. It works by blocking JAK1 enzymes that transmit inflammatory signals, reducing joint inflammation and skin symptoms. Due to risks of serious infections, blood clots, and cardiovascular events, it requires careful patient selection and monitoring.

Khối lượng phân tử

380,3700 g/mol

LogP

2,70

TPSA

78,30 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Rheumatoid Arthritis Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Atopic Dermatitis

Phân loại thuốc

L — L - Antineoplastic and Immunomodulating Agents

Cơ chế tác dụng

Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

Pharmacokinetics (PK)

Half-Life 9-14 hours

Pharmacodynamics (PD)

Cơ chế

Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12

                

                

                
                

                    
InChI

                    
InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H19F3N6O

                    

                    
                    

                        
HBD / HBA

                        
2 / 6

                    

                    
                    

                        
Liên kết có thể quay

                        
3

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
27

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
This oral JAK1-selective inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease in adults who have not responded adequately to other treatments. It works by blocking JAK1 enzymes that transmit inflammatory signals, reducing joint inflammation and skin symptoms. Due to risks of serious infections, blood clots, and cardiovascular events, it requires careful patient selection and monitoring.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Upadacitinib: Half-life: 9-14 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Upadacitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Methotrexate
                            Small molecule
                        
                        
                        
                            Tamoxifen
                            Small molecule
                        
                        
                        
                            Cyclosporine
                            Protein
                        
                        
                        
                            Tacrolimus
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3622821.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 58557659.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.